Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock

Eli Lilly‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S&P 500’s performance over the past three years.

Source link

About The Author

Scroll to Top